Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dymista in persistent moderate-to-severe allergic rhinitis
NCT02238353Phase 4
Key facts
- Status
- Unknown
- Start
- Oct 2014
- Primary completion
- Dec 2015
- Countries
- 1
- Sponsor
- UZ Leuven
- Modality
- Orthosteric Ligands
- Conditions
- allergic rhinitis (AR)
01
Overview
Phase 4, randomised, double-blind trial of azelastine + fluticasone in allergic rhinitis (AR), sponsored by UZ Leuven. Status: unknown.
02
Design
- Study design
- RandomizedDouble-blind
03
Who it enrols
Patients aged 18-60 with persistent moderate/severe allergic rhinitis, house dust mite allergy, nasal eosinophilia > 5%, and nasal hyperreactivity.
04
Registry description
Comparative analysis of the efficacy of intranasal MP29-02 (a novel formulation of azelastine and FP) has already been conducted in patients with moderate-to-severe seasonal AR. The combination formulation appeared to be superior in these patients with better symptomatic relief. However, objective analysis of the effect of this treatment on nasal mediators and/or nasal hyperreactivity has not yet been performed and would help in understanding the additional benefit of the combination treatment over monotherapy with nasal corticosteroids.
Beyond the preview
Go deeper on NCT02238353.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02238353.